Paroxetine in depression

Zanardi, R. et al. (2000). Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. /. Clin. Psychopharmacol., 20(1), 105-7. 

Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ (2002) Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7 1115-1119 Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000) Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20 105-107 Zanardi R, Serretti A, Rossini D, et al (2001) Factors affecting fluvoxamine antidepressant activity influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50 323-330... 

Dunbar GC, Fuell DL The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Chn Psychopharmacol 6 [suppl 4) 81-90, 1992 Dunleavy DLF, Oswald 1 Phenelzine, mood response and sleep. Arch Gen Psychiatry 28 353-356, 1973... 

Melton ST, Kirkwood CK, Farrar TW, et al (1997). Economic evaluation of paroxetine and imipramine in depressed outpatient. PsychopharmacolBull t >y 93-100. 

Venlafaxine extended release, in doses of 75 to 225 mg/day, improves social anxiety, performance, and avoidance behavior with a reduction in disability.61 Treatment with venlafaxine results in response rates similar to those seen with paroxetine.60 Venlafaxine may be effective in SSRI non-responders.62 As with SSRIs, doses should be tapered slowly when discontinuing therapy. Tolerability is similar to that observed in depression trials with venlafaxine extended release. Common side effects are anorexia, dry mouth, nausea, insomnia, and sexual dysfunction. 

An open-label study of paroxetine and fluoxetine (Alonso et al, 1997) in depressed Hispanic (Mexican descent, n = 13) and non-Hispanic females (n = 13) showed no differences in response rates. At variance with the tricyclic data, Hispanic subjects complained of fewer side effects (2.2 2.0 vs. 5.1 2.5 p < 0.005), but twice as many terminated participation prior to study completion due to non-compliance, intolerable side effects or pregnancy. 

Paroxetine in the Treatment of Acute Major Depression in Adults A Systematic Re-Examination of Published and Unpublished Data from Randomized Trials , Canadian Medical Association Journal 178, no. 3 (2008) 296-305... 

Treatment with a selective serotonin reuptake inhibitor is usually initiated in depressed patients with AD. Paroxetine causes more anticholinergic side effects than the other selective serotonin reuptake inhibitors. Ven-lafaxine may also be used. 

Preskorn S (1994) Targeted pharmacotherapy in depression management comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 9(Suppl3) 13-19... 

Feighner JP, Cohn JB, Fabre LF Jr, Fieve RR, Mendels J, Shrivastava RK, Dunbar GC (1993) A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord 28 71-79... 

Roose SR Laghrissi-Thode F, Kennedy IS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. lAMA i998 279 287-29i. 

Findling, R.L., Reed, M.D., Myers, C., Riordan, M.A., Fiala, S., Branicky, L., Waldorf, B., and Blumer, J.L. (1999) Paroxetine pharmacokinetics in depressed children and adolescents. / Am Acad Child Adolesc Psychiatry 38 952-959. 

E. B., Winters, N.C., Oakes, R. and McCafferty, J.P. (2001) Efficacy of paroxetine in the treatment of adolescent major depression a randomized, controlled trial. / Am Acad Child Adolesc Psychiatry 40 762-772. 

Poirier, M.F. and Boyer, P. (1999) Venlafaxine and paroxetine in treatment-resistant depression double-blind, randomized comparison. Br J Psychiatry 175 12-16. 

Efficacy of paroxetine in the treatment of adolescent major depression a randomized, controlled trial. / Am Acad Child Adolesc Psychiatry 40 762-772. 

---